KLRK1 and melanoma: In order to determine whether an alteration of the NKG2D/NKG2D ligands activating pathway might be involved in the decreased susceptibility of melanoma tumor cells to NK-mediated lysis following CAFs CMs treatment, we first determined whether this pathway is involved in NK-mediated killing of the T1 cell line.